Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
NCT07122986 · View on ClinicalTrials.gov ↗
Study Summary
This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults.
Conditions Studied
Interventions
- DRUG E coli vaccine 1 Dose A
- DRUG E coli vaccine 1 Dose B
- DRUG E coli vaccine 2
- DRUG E coli vaccine 3
- DRUG E coli Vaccine 4 Dose A
Study Locations (11)
California
- Anaheim Clinical Trials, LLC — Anaheim
- Orange County Research Center — Lake Forest
- Diablo Clinical Research, Inc. — Walnut Creek
Tennessee
- Alliance for Multispecialty Research, LLC — Knoxville
- Alliance for Multispecialty Research, LLC — Knoxville
- University Eye Specialists, P.C. (Ophthalmologist) — Maryville
Florida
- Miami Eye Institute — Hollywood
- Research Centers of America — Hollywood
Ohio
- CTI Clinical Research Center — Cincinnati
- Senders Pediatrics — South Euclid
New York
- NYU Langone Health — New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2025-08-11 |
| Est. Completion | 2028-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07122986
The ClinicalTrials.gov registry entry for NCT07122986 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 5 interventions — of which E coli vaccine 1 Dose A is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07122986 reports 11 study locations spanning 5 distinct geographic areas — top geographies include California, Tennessee, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07122986 about?
NCT07122986 is a clinical study titled "A Study to Learn About a Vaccine Against E Coli in Healthy Adults". This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults.
What is the current status of trial NCT07122986?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 310 participants. The study started on 2025-08-11. Estimated completion is 2028-05-26.
What conditions does trial NCT07122986 study?
This clinical trial studies the following conditions: Healthy Participants. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07122986?
The interventions under investigation include: E coli vaccine 1 Dose A (DRUG), E coli vaccine 1 Dose B (DRUG), E coli vaccine 2 (DRUG), E coli vaccine 3 (DRUG), E coli Vaccine 4 Dose A (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07122986?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07122986 being conducted?
This trial has 11 study locations across California, Florida, New York, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.